Australia markets open in 7 hours 55 minutes

Humacyte, Inc. (HUMA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.9701+0.0401 (+0.81%)
As of 12:05PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close4.9300
Open4.9300
Bid4.9400 x 200
Ask5.0200 x 200
Day's range4.8500 - 5.1050
52-week range1.9600 - 9.9700
Volume738,519
Avg. volume2,367,309
Market cap591.859M
Beta (5Y monthly)1.61
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program

    – BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes – – Humacyte’s stem cell-derived islets observed to restore normal blood glucose in diabetic mice – – Non-human primate models of BVP implantation showed islet survival and continued insulin production – DURHAM, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human

  • GlobeNewswire

    Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)

    – Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte’s HAV – – BLA submission under Priority Review by FDA for the treatment of vascular trauma, supported by Phase 2/3 clinical trial results and real-world use treating wartime trauma injuries in Ukraine – DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantabl

  • GlobeNewswire

    Humacyte to Present at the Jefferies Global Healthcare Conference

    DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, in New York, NY on Thursday, June 6, 2024. Management will also be available for one-on-one meetings. Event: Jefferies Global Healt